GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

The interaction with GSK goes deeper, with Novartis and GSK announcing a merger of their OTC divisions to create a new joint venture which will be number one in the sector. This mirrors an earlier ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK acquires IDRx for $1 billion upfront, with $150M milestone payments; gains lead molecule IDRX-42 for gastrointestinal stromal tumors. IDRX-42 shows 53% ORR in 1 prior therapy line, targeting ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio. The purchase ...